BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 21320021)

  • 21. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol.
    Simon D; Nolte I; Eberle N; Abbrederis N; Killich M; Hirschberger J
    J Vet Intern Med; 2006; 20(4):948-54. PubMed ID: 16955821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma.
    Simon D; Moreno SN; Hirschberger J; Moritz A; Kohn B; Neumann S; Jurina K; Scharvogel S; Schwedes C; Reinacher M; Beyerbach M; Nolte I
    J Am Vet Med Assoc; 2008 Mar; 232(6):879-85. PubMed ID: 18341445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
    Verdonck LF; van Putten WL; Hagenbeek A; Schouten HC; Sonneveld P; van Imhoff GW; Kluin-Nelemans HC; Raemaekers JM; van Oers RH; Haak HL
    N Engl J Med; 1995 Apr; 332(16):1045-51. PubMed ID: 7898521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
    Alliot C
    J Clin Oncol; 2005 Jul; 23(21):4797-9; author reply 4799-800. PubMed ID: 16034060
    [No Abstract]   [Full Text] [Related]  

  • 25. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.
    Wang SL; Lee JJ; Liao AT
    Can Vet J; 2016 Mar; 57(3):271-6. PubMed ID: 26933263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of doxorubicin and COP for maintenance of remission in cats with lymphoma.
    Moore AS; Cotter SM; Frimberger AE; Wood CA; Rand WM; L'Heureux DA
    J Vet Intern Med; 1996; 10(6):372-5. PubMed ID: 8947869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma.
    Perry JA; Thamm DH; Eickhoff J; Avery AC; Dow SW
    Vet Comp Oncol; 2011 Mar; 9(1):55-64. PubMed ID: 21303454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma.
    Hosoya K; Kisseberth WC; Lord LK; Alvarez FJ; Lara-Garcia A; Kosarek CE; London CA; Couto CG
    J Vet Intern Med; 2007; 21(6):1355-63. PubMed ID: 18196747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Remission maintenance therapy of non-Hodgkin's lymphoma with CHOP protocol].
    Toki H; Okabe K; Ishikawa M; Fujii M; Kimura Y
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):260-4. PubMed ID: 6546489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
    Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
    Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
    Garrett LD; Thamm DH; Chun R; Dudley R; Vail DM
    J Vet Intern Med; 2002; 16(6):704-9. PubMed ID: 12465768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of chemotherapy for cats with alimentary malignant lymphoma: 21 cases (1993-1997).
    Zwahlen CH; Lucroy MD; Kraegel SA; Madewell BR
    J Am Vet Med Assoc; 1998 Oct; 213(8):1144-9. PubMed ID: 9787382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
    Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
    Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is maintenance chemotherapy appropriate for the management of canine malignant lymphoma?
    Hahn KA; Richardson RC; Teclaw RF; Cline JM; Carlton WW; DeNicola DB; Bonney PL
    J Vet Intern Med; 1992; 6(1):3-10. PubMed ID: 1548624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
    J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma.
    Zemann BI; Moore AS; Rand WM; Mason G; Ruslander DM; Frimberger AE; Wood CA; L'Heureux DA; Gliatto J; Cotter SM
    J Vet Intern Med; 1998; 12(6):465-70. PubMed ID: 9857340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
    Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
    Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
    Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
    Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.